Capital Cell

Aortyx is a pioneering company founded by researchers from IQS School of Engineering and Hospital Clínic de Barcelona. It specializes in developing endovascular devices designed to treat aortic diseases, focusing on tissue regeneration through mimicking the aorta's biomechanical environment.

Aortyx is a pioneering company founded by researchers from IQS School of Engineering and Hospital Clínic de Barcelona. It specializes in developing endovascular devices designed to treat aortic diseases, focusing on tissue regeneration through mimicking the aorta's biomechanical environment.

Aortyx is a pioneering company founded by researchers from IQS School of Engineering and Hospital Clínic de Barcelona. It specializes in developing endovascular devices designed to treat aortic diseases, focusing on tissue regeneration through mimicking the aorta's biomechanical environment.

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

Vytrus Biotech SL is a biotechnology company based in Barcelona, Spain, that specializes in the development, production, and commercialization of active ingredients derived from plant stem cells. Founded in 2009 as a spin-off from the University of Barcelona, the company leverages over 30 years of research in plant biotechnology to create high-value natural active ingredients primarily for the cosmetics and pharmaceutical industries. Its product offerings include a range of cosmetic solutions such as cell factor-rich plasma and phyto-peptidic fractions, as well as dermatologic and customized products. In 2016, the company changed its name from Phyture Biotech SL to Vytrus Biotech SL, reflecting its focus on innovative, plant-based active ingredients.

Capital Cell is a European equity crowdfunding platform based in Barcelona, Spain, that specializes in biotechnology and life sciences projects. Founded in 2014, the company serves as a meeting point for entrepreneurs and private investors, including venture capitalists and business angels, to facilitate funding for innovative medical science initiatives. By leveraging the power of the crowd, Capital Cell enables researchers and companies in the biotech sector to access a diverse pool of investment, thereby fostering the growth and development of cutting-edge solutions in healthcare.